header logo image

GENFIT announces satisfactory preliminary results of its OCEANEs’ partial buyback offer

November 30th, 2020 7:57 am

Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that:

See original here:
GENFIT announces satisfactory preliminary results of its OCEANEs’ partial buyback offer

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick